

**WEST**

Help

Logout

Interrupt

Main Menu

Search Form

Posting Counts

Show S Numbers

Edit S Numbers

Preferences

09/837998

Serial # J  
Search results for  
Paper # 6**Search Results -**

Terms	Documents
vaccinia and E3L and 184	2

**Database:**

US Patents Full-Text Database  
US Pre-Grant Publication Full-Text Database  
JPO Abstracts Database  
EPO Abstracts Database  
Derwent World Patents Index  
IBM Technical Disclosure Bulletins

Refine Search:

vaccinia and E3L and 184

Clear

**Search History****Today's Date: 10/18/2001**

<u>DB Name</u>	<u>Query</u>	<u>Hit Count</u>	<u>Set Name</u>
USPT,PGPB,JPAB,EPAB,DWPI,TDBD	vaccinia and E3L and 184	2	<u>L6</u>
USPT,PGPB,JPAB,EPAB,DWPI,TDBD	12 and vaccine\$	5	<u>L5</u>
USPT,PGPB,JPAB,EPAB,DWPI,TDBD	vaccinia and E3L near5 expression near3 vector\$	0	<u>L4</u>
USPT,PGPB,JPAB,EPAB,DWPI,TDBD	vaccinia and E3L near5 delet\$ near10 expression near3 vector\$	0	<u>L3</u>
USPT,PGPB,JPAB,EPAB,DWPI,TDBD	vaccinia and E3L near5 delet\$	6	<u>L2</u>
USPT,PGPB,JPAB,EPAB,DWPI,TDBD	vaccinia and E3L	19	<u>L1</u>

**WEST**[Generate Collection](#)**Search Results - Record(s) 1 through 19 of 19 returned.**☐ 1. Document ID: US 6287570 B1

L1: Entry 1 of 19

File: USPT

Sep 11, 2001

US-PAT-NO: 6287570

DOCUMENT-IDENTIFIER: US 6287570 B1

TITLE: Vaccine against swine influenza virus

DATE-ISSUED: September 11, 2001

## INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Foley; Patricia L.	Huxley	IA	50124	

US-CL-CURRENT: 424/199.1; 424/232.1, 424/93.1, 424/93.2,  
435/235.1

Full	Title	Citation	Front	Review	Classification	Date	Reference	Claims	MMC	Draw Desc	Image
------	-------	----------	-------	--------	----------------	------	-----------	--------	-----	-----------	-------

☐ 2. Document ID: US 6267965 B1

L1: Entry 2 of 19

File: USPT

Jul 31, 2001

US-PAT-NO: 6267965

DOCUMENT-IDENTIFIER: US 6267965 B1

TITLE: Recombinant poxvirus--cytomegalovirus compositions and  
uses

DATE-ISSUED: July 31, 2001

## INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Paoletti; Enzo	Delmar	NY		
Pincus; Steven E.	East Greenbush	NY		
Cox; William I.	Troy	NY		
Kauffman; Elizabeth K.	Averill Park	NY		

US-CL-CURRENT: 424/199.1; 424/204.1, 424/230.1, 424/232.1,  
435/235.1, 435/320.1, 530/300, 530/388.1, 536/23.72

Full	Title	Citation	Front	Review	Classification	Date	Reference	Claims	MMC	Draw Desc	Image
------	-------	----------	-------	--------	----------------	------	-----------	--------	-----	-----------	-------

☐ 3. Document ID: US 6183752 B1

L1: Entry 3 of 19

File: USPT

Feb 6, 2001

US-PAT-NO: 6183752

DOCUMENT-IDENTIFIER: US 6183752 B1

TITLE: Restenosis/atherosclerosis diagnosis, prophylaxis and therapy

DATE-ISSUED: February 6, 2001

## INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Epstein; Stephen E.	Rockville	MD		
Finkel; Toren	Bethesda	MD		
Speir; Edith	Annandale	VA		
Zhou; Yi Fu	Bethesda	MD		
Zhu; Jianhui	Bethesda	MD		
Erdile; Lorne	Loudonville	NY		
Pincus; Steven	East Greenbush	NY		

US-CL-CURRENT: 424/199.1; 424/230.1, 424/277.1, 424/93.2, 435/320.1, 514/44

Full	Title	Citation	Front	Review	Classification	Date	Reference
------	-------	----------	-------	--------	----------------	------	-----------

EMMC	Draw Desc	Image
------	-----------	-------

☐ 4. Document ID: US 6156496 A

L1: Entry 4 of 19

File: USPT

Dec 5, 2000

US-PAT-NO: 6156496

DOCUMENT-IDENTIFIER: US 6156496 A

TITLE: Method for selective inactivation of viral replication

DATE-ISSUED: December 5, 2000

## INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Miles; Vincent J.	Chestnut Hill	MA		
Mathews; Michael B.	Montclair	NJ		
Katze; Michael G.	Seattle	WA		
Watson; Julia C.	San Jose	CA		
Witherell; Gary	Orinda	CA		

US-CL-CURRENT: 435/5; 435/325, 435/455, 435/6, 435/7.1, 514/44, 536/23.1, 536/24.5

Full	Title	Citation	Front	Review	Classification	Date	Reference
------	-------	----------	-------	--------	----------------	------	-----------

EMMC	Draw Desc	Image
------	-----------	-------

☐ 5. Document ID: US 6130066 A

L1: Entry 5 of 19

File: USPT

Oct 10, 2000

US-PAT-NO: 6130066

DOCUMENT-IDENTIFIER: US 6130066 A

TITLE: Vectors having enhanced expression and methods of making  
and uses thereof

DATE-ISSUED: October 10, 2000

## INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP	CODE	COUNTRY
Tartaglia; James	Schenectady	NY			
Cox; William I.	Sand Lake	NY			
Gettig; Russell Robert	Averill Park	NY			
Martinez; Hector	Menands	NY			
Paoletti; Enzo	Delmar	NY			
Pincus; Steven E.	East Greenbush	NY			

US-CL-CURRENT: 435/69.1; 435/320.1, 435/91.41, 536/23.72

Full	Title	Citation	Front	Review	Classification	Date	Reference
------	-------	----------	-------	--------	----------------	------	-----------

FIG	Draw Desc	Image
-----	-----------	-------

☐ 6. Document ID: US 6093700 A

L1: Entry 6 of 19

File: USPT

Jul 25, 2000

US-PAT-NO: 6093700

DOCUMENT-IDENTIFIER: US 6093700 A

TITLE: Method of inducing an immune response using vaccinia  
virus recombinants encoding GM-CSF

DATE-ISSUED: July 25, 2000

## INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP	CODE	COUNTRY
Mastrangelo; Michael J.	Jenkintown	PA			
Lattime; Edmund C.	Princeton	NJ			
Berd; David	Wyncote	PA			
Eisenlohr; Laurence C.	Merion	PA			

US-CL-CURRENT: 514/44; 435/320.1

Full	Title	Citation	Front	Review	Classification	Date	Reference
------	-------	----------	-------	--------	----------------	------	-----------

FIG	Draw Desc	Image
-----	-----------	-------

☐ 7. Document ID: US 6030785 A

L1: Entry 7 of 19

File: USPT

Feb 29, 2000

US-PAT-NO: 6030785

DOCUMENT-IDENTIFIER: US 6030785 A

TITLE: Screening methods to identify agents that selectively inhibit hepatitis C virus replication

DATE-ISSUED: February 29, 2000

## INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Katze; Michael G.	Seattle	WA		
Gale, Jr.; Michael J.	Monroe	WA		

US-CL-CURRENT: 435/6; 435/254.21, 435/375

Full	Title	Citation	Front	Review	Classification	Date	Reference
------	-------	----------	-------	--------	----------------	------	-----------

FWMC	Draw Desc	Image
------	-----------	-------

☐ 8. Document ID: US 6004777 A

L1: Entry 8 of 19

File: USPT

Dec 21, 1999

US-PAT-NO: 6004777

DOCUMENT-IDENTIFIER: US 6004777 A

TITLE: Vectors having enhanced expression, and methods of making and uses thereof

DATE-ISSUED: December 21, 1999

## INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Tartaglia; James	Schenectady	NY		
Jacobs; Bertram L.	Phoenix	AZ		
Goebel; Scott J.	Ballston Spa	NY		
Cox; William I.	Sand Lake	NY		
Gettig; Russell Robert	Averill Park	NY		
Pincus; Steven E.	East Greenbush	NY		
Paoletti; Enzo	Delmar	NY		

US-CL-CURRENT: 435/69.1; 435/320.1, 435/91.41, 536/23.1,  
536/23.72

Full	Title	Citation	Front	Review	Classification	Date	Reference
------	-------	----------	-------	--------	----------------	------	-----------

FWMC	Draw Desc	Image
------	-----------	-------

☐ 9. Document ID: US 5997878 A

L1: Entry 9 of 19

File: USPT

Dec 7, 1999

US-PAT-NO: 5997878

DOCUMENT-IDENTIFIER: US 5997878 A

TITLE: Recombinant poxvirus-cytomegalovirus, compositions and uses

DATE-ISSUED: December 7, 1999

## INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Paoletti; Enzo	Delmar	NY		
Pincus; Steven E.	East Greenbush	NY		
Cox; William I.	Sand Lake	NY		
Kauffman; Elizabeth B.	Averill Park	NY		

US-CL-CURRENT: 424/199.1; 424/230.1, 424/232.1, 435/235.1,  
435/320.1, 435/69.1, 435/69.3

Full	Title	Citation	Front	Review	Classification	Date	Reference
------	-------	----------	-------	--------	----------------	------	-----------

RMIC	Draw Desc	Image
------	-----------	-------

☐ 10. Document ID: US 5990388 A

L1: Entry 10 of 19

File: USPT

Nov 23, 1999

US-PAT-NO: 5990388

DOCUMENT-IDENTIFIER: US 5990388 A

TITLE: Resistance to viruses and viroids in transgenic plants and animals expressing dsRNA-binding protein

DATE-ISSUED: November 23, 1999

## INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Roth; Don Allen	Laramie	WY		
Langland; Jeffrey Olaf	Laramie	WY		

US-CL-CURRENT: 800/301; 435/320.1, 800/280, 800/317.2,  
800/317.3

Full	Title	Citation	Front	Review	Classification	Date	Reference
------	-------	----------	-------	--------	----------------	------	-----------

RMIC	Draw Desc	Image
------	-----------	-------

☐ 11. Document ID: US 5990091 A

L1: Entry 11 of 19

File: USPT

Nov 23, 1999

US-PAT-NO: 5990091

DOCUMENT-IDENTIFIER: US 5990091 A

TITLE: Vectors having enhanced expression, and methods of making and uses thereof

DATE-ISSUED: November 23, 1999

## INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Tartaglia; James	Schenectady	NY		
Cox; William I.	Sand Lake	NY		
Gettig; Russell Robert	Averill Park	NY		
Martinez; Hector	Menands	NY		
Paoletti; Enzo	Delmar	NY		
Pincus; Steven E.	East Greenbush	NY		

US-CL-CURRENT: 514/44; 424/93.2, 435/320.1, 435/69.1, 435/91.4,  
435/91.41

Full	Title	Citation	Front	Review	Classification	Date	Reference
------	-------	----------	-------	--------	----------------	------	-----------

RMK	Draw Desc	Image
-----	-----------	-------

☐ 12. Document ID: US 5942235 A

L1: Entry 12 of 19

File: USPT

Aug 24, 1999

US-PAT-NO: 5942235

DOCUMENT-IDENTIFIER: US 5942235 A

TITLE: Recombinant poxvirus compositions and methods of inducing immune responses

DATE-ISSUED: August 24, 1999

## INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Paoletti; Enzo	Delmar	NY		

US-CL-CURRENT: 424/232.1; 424/199.1, 424/93.2, 435/320.1,  
435/456

Full	Title	Citation	Front	Review	Classification	Date	Reference
------	-------	----------	-------	--------	----------------	------	-----------

RMK	Draw Desc	Image
-----	-----------	-------

☐ 13. Document ID: US 5833975 A

L1: Entry 13 of 19

File: USPT

Nov 10, 1998

US-PAT-NO: 5833975

DOCUMENT-IDENTIFIER: US 5833975 A

TITLE: Canarypox virus expressing cytokine and/or  
tumor-associated antigen DNA sequence

DATE-ISSUED: November 10, 1998

## INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Paoletti; Enzo	Delmar	NY		
Tartaglia; James	Schenectady	NY		
Cox; William I.	Troy	NY		

US-CL-CURRENT: 424/93.2; 435/320.1, 435/456, 435/69.3,  
435/69.5, 435/69.51, 435/69.52

Full	Title	Citation	Front	Review	Classification	Date	Reference
------	-------	----------	-------	--------	----------------	------	-----------

KWIC	Draw Desc	Image
------	-----------	-------

☐ 14. Document ID: US 5795713 A

L1: Entry 14 of 19

File: USPT

Aug 18, 1998

US-PAT-NO: 5795713

DOCUMENT-IDENTIFIER: US 5795713 A

TITLE: Methods for identifying inducers and inhibitors of  
programmed cell death

DATE-ISSUED: August 18, 1998

## INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Roizman; Bernard	Chicago	IL		
He; Bin	Chicago	IL		

US-CL-CURRENT: 435/5; 435/15, 435/21

Full	Title	Citation	Front	Review	Classification	Date	Reference
------	-------	----------	-------	--------	----------------	------	-----------

KWIC	Draw Desc	Image
------	-----------	-------

☐ 15. Document ID: US 5738985 A

L1: Entry 15 of 19

File: USPT

Apr 14, 1998

US-PAT-NO: 5738985

DOCUMENT-IDENTIFIER: US 5738985 A

TITLE: Method for selective inactivation of viral replication

DATE-ISSUED: April 14, 1998

## INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP	CODE	COUNTRY
Miles; Vincent J.	San Ramon	CA			
Mathews; Michael B.	Cold Spring Harbor	NY			
Katze; Michael G.	Seattle	WA			

US-CL-CURRENT: 435/5; 435/254.2, 435/6, 435/7.1

Full	Title	Citation	Front	Review	Classification	Date	Reference
------	-------	----------	-------	--------	----------------	------	-----------

FIG	Draw Desc	Image
-----	-----------	-------

☐ 16. Document ID: WO 200073487 A1

L1: Entry 16 of 19

File: DWPI

Dec 7, 2000

DERWENT-ACC-NO: 2001-041152

DERWENT-WEEK: 200105

COPYRIGHT 2001 DERWENT INFORMATION LTD

TITLE: Vaccinia virus with amino acids deleted from the E3L gene product, which reduces virulence and improves efficacy, useful as a vaccine

INVENTOR: BRANDT, T; JACOBS, B

PRIORITY-DATA: 1999US-0136277 (May 27, 1999)

## PATENT-FAMILY:

PUB-NO	PUB-DATE	LANGUAGE	PAGES	MAIN-IPC
WO 200073487 A1	December 7, 2000	E	012	C12P021/06

INT-CL (IPC): C07H 21/02; C07H 21/04; C12N 15/39; C12N 15/64; C12P 21/06

Full	Title	Citation	Front	Review	Classification	Date	Reference
------	-------	----------	-------	--------	----------------	------	-----------

FIG	Draw Desc	Image
-----	-----------	-------

☐ 17. Document ID: AU 200042469 A, WO 200062735 A2

L1: Entry 17 of 19

File: DWPI

Nov 2, 2000

DERWENT-ACC-NO: 2000-656408  
DERWENT-WEEK: 200107  
COPYRIGHT 2001 DERWENT INFORMATION LTD

TITLE: Treating neoplasms including cancer and solid tumors in a mammal comprises administering interferon-sensitive, replication-competent clonal RNA or DNA viruses such as paramyxovirus and herpesvirus

INVENTOR: GROENE, W S; LORENCE, R M ; RABIN, H ; ROBERTS, M S ;  
VON BORSTEL, R W

PRIORITY-DATA: 1999US-0292376 (April 15, 1999)

PATENT-FAMILY:

PUB-NO	PUB-DATE	LANGUAGE	PAGES	MAIN-IPC
AU 200042469 A	November 2, 2000		000	A61K000/00
WO 200062735 A2	October 26, 2000	E	108	A61K000/00

INT-CL (IPC): A61K 0/00

Full	Title	Citation	Front	Review	Classification	Date	Reference
------	-------	----------	-------	--------	----------------	------	-----------

KWIC	Draw Desc	Image
------	-----------	-------

☐ 18. Document ID: WO 9955910 A1

L1: Entry 18 of 19

File: DWPI

Nov 4, 1999

DERWENT-ACC-NO: 2000-052813  
DERWENT-WEEK: 200004  
COPYRIGHT 2001 DERWENT INFORMATION LTD

TITLE: Inducing apoptosis in a target cell useful for treating cancer

INVENTOR: JACOBS, B L

PRIORITY-DATA: 1998US-0082976 (April 24, 1998)

PATENT-FAMILY:

PUB-NO	PUB-DATE	LANGUAGE	PAGES	MAIN-IPC
WO 9955910 A1	November 4, 1999	E	025	C12Q001/68

INT-CL (IPC): A61K 48/00; C07H 21/02; C07H 21/04; C12N 15/85;  
C12N 15/86; C12Q 1/68

Full	Title	Citation	Front	Review	Classification	Date	Reference
------	-------	----------	-------	--------	----------------	------	-----------

KWIC	Draw Desc	Image
------	-----------	-------

☐ 19. Document ID: CN 1281336 A, WO 9918799 A1, AU 9896038 A, EP 1032269 A1,  
HU 200003911 A2

L1: Entry 19 of 19

File: DWPI

Jan 24, 2001

DERWENT-ACC-NO: 1999-277360

DERWENT-WEEK: 200130

COPYRIGHT 2001 DERWENT INFORMATION LTD

TITLE: Treating tumours by infection with interferon-sensitive viruses - effective against large tumours that do not respond to chemotherapy

INVENTOR: GROENE, W S ; LORENCE, R M ; RABIN, H ; ROBERTS, M S ; VON BORSTEL, R W

PRIORITY-DATA: 1997US-0948244 (October 9, 1997)

## PATENT-FAMILY:

PUB-NO	PUB-DATE	LANGUAGE	PAGES	MAIN-IPC
CN 1281336 A	January 24, 2001		000	A01N063/00
WO 9918799 A1	April 22, 1999	E	094	A01N063/00
AU 9896038 A	May 3, 1999		000	A01N063/00
EP 1032269 A1	September 6, 2000	E	000	A01N063/00
HU 200003911 A2	February 28, 2001		000	A01N063/00

INT-CL (IPC): A01N 63/00

Full	Title	Citation	Front	Review	Classification	Date	Reference
------	-------	----------	-------	--------	----------------	------	-----------

PMAC	Draw Desc	Image
------	-----------	-------

---

Generate Collection

Terms	Documents
vaccinia and E3L	19

---

Display

100

Documents, starting with Document:

19

Display Format:

Change Format

HILIGHT set on as ''

**HILIGHT set on as ''**

? begin 5,6,55,154,155,156,312,399,biotech,biosci

Set Items Description

? s vaccinia and E3L and vaccine?

61724 VACCINIA

422 E3L

594465 VACCINE?

S1 12 VACCINIA AND E3L AND VACCINE?

? rd s1

...completed examining records

S2 11 RD S1 (unique items)

? d s2/3/1-11

Display 2/3/1 (Item 1 from file: 399)

DIALOG(R)File 399:CA SEARCH(R)

(c) 2001 AMERICAN CHEMICAL SOCIETY. All rts. reserv.

129226634 CA: 129(18)226634d PATENT

Viral vectors having enhanced expression, and methods of making and uses thereof

INVENTOR(AUTHOR): Tartaglia, James; Cox, William I.; Gettig, Russell R.; Martinez, Hector; Paoletti, Enzo; Pincus, Steven E.

LOCATION: USA

ASSIGNEE: Virogenetics Corp.

PATENT: PCT International ; WO 9840501 A1 DATE: 19980917

APPLICATION: WO 98US2669 (19980213) \*US 816155 (19970312)

PAGES: 102 pp. CODEN: PIXXD2 LANGUAGE: English CLASS: C12N-015/64A; C12N-015/67B; C12N-015/86B; A61K-048/00B DESIGNATED COUNTRIES: AU; CA; JP

DESIGNATED REGIONAL: AT; BE; CH; DE; DK; ES; FI; FR; GB; GR; IE; IT; LU; MC; NL; PT; SE

- end of record -

? d s2/9/1-11

Display 2/9/1 (Item 1 from file: 399)

DIALOG(R)File 399:CA SEARCH(R)

(c) 2001 AMERICAN CHEMICAL SOCIETY. All rts. reserv.

129226634 CA: 129(18)226634d PATENT

Viral vectors having enhanced expression, and methods of making and uses thereof

INVENTOR(AUTHOR): Tartaglia, James; Cox, William I.; Gettig, Russell R.; Martinez, Hector; Paoletti, Enzo; Pincus, Steven E.

LOCATION: USA

ASSIGNEE: Virogenetics Corp.

PATENT: PCT International ; WO 9840501 A1 DATE: 19980917

APPLICATION: WO 98US2669 (19980213) \*US 816155 (19970312)

PAGES: 102 pp. CODEN: PIXXD2 LANGUAGE: English CLASS: C12N-015/64A; C12N-015/67B; C12N-015/86B; A61K-048/00B DESIGNATED COUNTRIES: AU; CA; JP

DESIGNATED REGIONAL: AT; BE; CH; DE; DK; ES; FI; FR; GB; GR; IE; IT; LU; MC; NL; PT; SE

SECTION:

CA203002 Biochemical Genetics

CA210XXX MICROBIAL, ALGAL, AND FUNGAL BIOCHEMISTRY

-more-

?

Display 2/9/1 (Item 1 from file: 399)  
DIALOG(R) File 399:CA SEARCH(R)  
(c) 2001 AMERICAN CHEMICAL SOCIETY. All rts. reserv.  
CA215XXX Immunochemistry  
CA263XXX Pharmaceuticals  
IDENTIFIERS: vaccinia poxvirus gene expression vector  
DESCRIPTORS:  
Canarypox virus...  
ALVAC deriv. of; viral vaccinia and canarypox vectors having enhanced  
expression, and methods of making and uses thereof  
Genes(microbial)...  
A1L; viral vaccinia and canarypox vectors having enhanced expression,  
and methods of making and uses thereof  
Genes(microbial)...  
A2L; viral vaccinia and canarypox vectors having enhanced expression,  
and methods of making and uses thereof  
Genes(microbial)...  
A7; viral vaccinia and canarypox vectors having enhanced expression,  
and methods of making and uses thereof  
Genes(microbial)...

-more-

?

Display 2/9/1 (Item 1 from file: 399)  
DIALOG(R) File 399:CA SEARCH(R)  
(c) 2001 AMERICAN CHEMICAL SOCIETY. All rts. reserv.  
D6; viral vaccinia and canarypox vectors having enhanced expression,  
and methods of making and uses thereof  
Genes(microbial)...  
EBER; viral vaccinia and canarypox vectors having enhanced expression,  
and methods of making and uses thereof  
Genes(microbial)...  
E3L; viral vaccinia and canarypox vectors having enhanced expression,  
and methods of making and uses thereof  
Protein formation factors... Transcription factors...  
genes for; viral vaccinia and canarypox vectors having enhanced  
expression, and methods of making and uses thereof  
Genes(microbial)...  
G8R; viral vaccinia and canarypox vectors having enhanced expression,  
and methods of making and uses thereof  
Genes(microbial)...  
H4L; viral vaccinia and canarypox vectors having enhanced expression,  
and methods of making and uses thereof

-more-

?

Display 2/9/1 (Item 1 from file: 399)  
DIALOG(R) File 399:CA SEARCH(R)  
(c) 2001 AMERICAN CHEMICAL SOCIETY. All rts. reserv.  
Genes(microbial)...  
H5R; viral vaccinia and canarypox vectors having enhanced expression,  
and methods of making and uses thereof  
Genes(microbial)...  
K3L; viral vaccinia and canarypox vectors having enhanced expression,  
and methods of making and uses thereof  
Vaccinia virus...  
NYVAC deriv. of; viral vaccinia and canarypox vectors having enhanced

expression, and methods of making and uses thereof  
Genes(microbial)...  
TRBP; viral vaccinia and canarypox vectors having enhanced expression,  
and methods of making and uses thereof  
Genes(microbial)...  
VAI; viral vaccinia and canarypox vectors having enhanced expression,  
and methods of making and uses thereof  
Virus vectors...  
vCP1452 and vCP1433; viral vaccinia and canarypox vectors having

-more-

?

Display 2/9/1 (Item 1 from file: 399)  
DIALOG(R)File 399:CA SEARCH(R)  
(c) 2001 AMERICAN CHEMICAL SOCIETY. All rts. reserv.  
enhanced expression, and methods of making and uses thereof  
Gene expression... Immunity... Poxviridae... Promoter(genetic element)...  
Vaccines...  
viral vaccinia and canarypox vectors having enhanced expression, and  
methods of making and uses thereof

- end of record -

?

Display 2/9/2 (Item 1 from file: 34)  
DIALOG(R)File 34:SciSearch(R) Cited Ref Sci  
(c) 2001 Inst for Sci Info. All rts. reserv.  
  
07097015 Genuine Article#: 123ZJ Number of References: 58  
Title: Analysis of genomic rearrangement and subsequent gene deletion of  
the attenuated Orf virus strain D1701  
Author(s): Cottone R; Buttner M; Bauer B; Henkel M; Hettich E; Rziha HJ  
(REPRINT)  
Corporate Source: FED RES CTR VIRUS DIS ANIM, INST VACCINES, PAUL EHRLICH  
STR 28/D-72076 TUBINGEN//GERMANY/ (REPRINT); FED RES CTR VIRUS DIS  
ANIM, INST VACCINES/D-72076 TUBINGEN//GERMANY/  
Journal: VIRUS RESEARCH, 1998, V56, N1 (JUL), P53-67  
ISSN: 0168-1702 Publication date: 19980700  
Publisher: ELSEVIER SCIENCE BV, PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS  
Language: English Document Type: ARTICLE  
Geographic Location: GERMANY  
Subfile: CC LIFE--Current Contents, Life Sciences  
Journal Subject Category: VIROLOGY  
Abstract: The orf virus (OV) strain D1701 belongs to the genetically

-more-

?

Display 2/9/2 (Item 1 from file: 34)  
DIALOG(R)File 34:SciSearch(R) Cited Ref Sci  
(c) 2001 Inst for Sci Info. All rts. reserv.  
heterogenous parapoxvirus (PPV) genus of the family Poxviridae. The  
attenuated OV D1701 has been licensed as a live **vaccine** against  
contagious ecthyma in sheep. Detailed knowledge on the genetic  
structure and organization of this PPV **vaccine** strain is an  
important prerequisite to reveal possible genetic mechanisms of PPV  
attenuation. The present study demonstrates a genomic map of the  
approximately 158 kbp DNA of OV D1701 established by hybridization

studies of cloned restriction fragments covering the complete viral genome. The results show an enlargement of the inverted terminal repeats (ITR) to up to 18 kbp due to recombination between nonhomologous sequences during cell culture adaptation. DNA sequencing of the region adjacent to the ITR junction revealed the absence of one open reading frame designated E2L. In contrast to a transposition-deletion variant of the New Zealand OV strain NZ2 (Fleming et al., 1995) the two genes **E3L** (a homologue of dUTPase) and G1L neighbouring E2L are retained in OV D1701. DNA and RNA analyses proved the presence of E2L gene in wild-type OV isolated directly from

-more-

?

Display 2/9/2 (Item 1 from file: 34)  
DIALOG(R)File 34:SciSearch(R) Cited Ref Sci  
(c) 2001 Inst for Sci Info. All rts. reserv.  
scab material. The data presented indicate that the E2L gene is nonessential for virus replication in vitro and in vivo, and may represent one important viral gene in determining virulence and pathogenesis of OV. (C) 1998 Elsevier Science B.V. All rights reserved.  
Descriptors--Author Keywords: parapoxvirus ; attenuated orf virus D1701 ; genomic map ; gene deletion  
Identifiers--Keyword Plus(R): INVERTED TERMINAL REPETITION; RESTRICTION ENDONUCLEASE ANALYSIS; THYMIDINE KINASE GENE; **VACCINIA** VIRUS; RABBIT POXVIRUS; COWPOX VIRUS; MONKEYPOX VIRUS; FOWLPOX VIRUS; DNA-SEQUENCE; HUMAN-CELLS  
Cited References:  
ARCHARD LC, 1979, V45, P51, J GEN VIROL  
ARCHARD LC, 1984, V65, P875, J GEN VIROL  
BAROUDY BM, 1982, V28, P315, CELL  
BINNS MM, 1988, V69, P1275, J GEN VIROL  
BLOOM DC, 1991, V65, P1530, J VIROL  
BULLER RML, 1991, V55, P80, MICROBIOL REV

-more-

?

Display 2/9/2 (Item 1 from file: 34)  
DIALOG(R)File 34:SciSearch(R) Cited Ref Sci  
(c) 2001 Inst for Sci Info. All rts. reserv.  
CHOMCZYNSKI P, 1987, V162, P156, ANAL BIOCHEM  
DALLO S, 1987, V159, P408, VIROLOGY  
DRILLIEN R, 1981, V111, P488, VIROLOGY  
DRILLIEN R, 1987, V160, P203, VIROLOGY  
DUMBELL KR, 1980, V286, P29, NATURE  
EPOSITO JJ, 1978, V89, P53, VIROLOGY  
ESPOSITO JJ, 1981, V109, P231, VIROLOGY  
FLEMING SB, 1991, V97, P207, GENE  
FLEMING SB, 1995, V76, P2969, J GEN VIROL  
FLEMING SB, 1997, V71, P4857, J VIROL  
FLEMING SB, 1992, V187, P464, VIROLOGY  
FLEMING SB, 1993, V195, P175, VIROLOGY  
FRASER KM, 1990, V176, P379, VIROLOGY  
GARON CF, 1978, V75, P4863, P NATL ACAD SCI USA  
GASSMANN U, 1985, V83, P17, ARCH VIROL  
GILLARD S, 1986, V83, P5573, P NATL ACAD SCI USA  
GOEBEL SJ, 1990, V179, P247, VIROLOGY

-more-

?

Display 2/9/2 (Item 1 from file: 34)  
DIALOG(R)File 34:SciSearch(R) Cited Ref Sci  
(c) 2001 Inst for Sci Info. All rts. reserv.  
KOTWAL GJ, 1988, V167, P524, VIROLOGY  
KROCZEK RA, 1990, V184, P90, ANAL BIOCHEM  
LAI ACK, 1989, V12, P239, VIRUS RES  
LAKE JR, 1980, V48, P135, J GEN VIROL  
LYTTLE DJ, 1994, V68, P84, J VIROL  
MACKETT M, 1979, V45, P683, J GEN VIROL  
MAYR A, 1981, V28, P535, ZBL VET MED B  
MCGEOCH DJ, 1990, V18, P4105, NUCLEIC ACIDS RES  
MERCER AA, 1987, V157, P1, VIROLOGY  
MERCER AA, 1989, V172, P665, VIROLOGY  
MERCER AA, 1995, V212, P698, VIROLOGY  
MERCER AA, 1996, V13, P175, VIRUS GENES  
MEYER H, 1991, V72, P1031, J GEN VIROL  
MOSS B, 1990, V59, P661, ANNU REV BIOCHEM  
MOSS B, 1981, V40, P387, J VIROL  
MOYER RW, 1980, V22, P545, CELL  
MOYER RW, 1980, V102, P119, VIROLOGY

-more-

?

Display 2/9/2 (Item 1 from file: 34)  
DIALOG(R)File 34:SciSearch(R) Cited Ref Sci  
(c) 2001 Inst for Sci Info. All rts. reserv.  
PAEZ E, 1985, V82, P3365, P NATL ACAD SCI USA  
PANICALI D, 1981, V37, P1000, J VIROL  
PERKUS ME, 1990, V179, P276, VIROLOGY  
PERKUS ME, 1991, V180, P406, VIROLOGY  
PICKUP DJ, 1984, V81, P6817, P NATL ACAD SCI USA  
PYLES RB, 1992, V66, P6706, J VIROL  
RAFII F, 1985, V84, P283, ARCH VIROL  
REED KC, 1985, V13, P7207, NUCLEIC ACIDS RES  
ROBINSON AJ, 1982, V71, P43, ARCH VIROL  
ROBINSON AJ, 1992, P285, RECOMBINANT POXVIRUS  
ROBINSON AJ, 1981, V51, P771, VET B  
ROBINSON AJ, 1987, V157, P13, VIROLOGY  
SULLIVAN JT, 1995, V9, P277, VIRUS GENES  
TURNER PC, 1990, V163, P125, CURR TOP MICROBIOL  
WITTEK R, 1980, V21, P277, CELL  
WITTEK R, 1977, V23, P669, J VIROL  
WITTEK R, 1978, V28, P171, J VIROL

-more-

?

Display 2/9/2 (Item 1 from file: 34)  
DIALOG(R)File 34:SciSearch(R) Cited Ref Sci  
(c) 2001 Inst for Sci Info. All rts. reserv.  
YUEN L, 1987, V84, P6417, P NATL ACAD SCI USA

- end of record -

?

Display 2/9/3 (Item 1 from file: 71)  
DIALOG(R)File 71:ELSEVIER BIOBASE  
(c) 2001 Elsevier Science B.V. All rts. reserv.

00293382 95102809

Distinct patterns of IFN sensitivity observed in cells infected with

**vaccinia** K3Lsup - and E3Lsup - mutant viruses

Beattie E.; Paoletti E.; Tartaglia J.

ADDRESS: J. Tartaglia, Virogenetics Corporation, Rensselaer Technology  
Park, 465 Jordan Road, Troy, NY 12180, United States

Journal: Virology, 210/2 (254-263), 1995, United States

PUBLICATION DATE: 19950000

CODEN: VIRLA

ISSN: 0042-6822

DOCUMENT TYPE: Article

LANGUAGES: English

SUMMARY LANGUAGES: English

Recent results have implicated a role for both the VV K3Lsup - and  
**E3L**-encoded gene products in conferring VV with an IFN-resistant  
phenotype (Beattie et al., Virology 183, 419-422, 1991; Beattie et al., J.

-more-

?

Display 2/9/3 (Item 1 from file: 71)

DIALOG(R)File 71:ELSEVIER BIOBASE

(c) 2001 Elsevier Science B.V. All rts. reserv.

Virol. 69, 499-505, 1995). As a means of further establishing the  
mechanisms by which these functions mediate this process in VV-infected  
cells, we have further assessed the IFN phenotype in K3Lsup - (vP872) and  
E3Lsup - (vP1080) virus-infected cells. Biochemical and molecular  
biological analyses were performed comparing the effects of IFN on  
wild-type as well as K3Lsup - and E3Lsup - virus-infected cells. Expression  
analyses of the K3L and **E3L** gene products revealed that both are  
evidenced in virus-infected cells as early as 0.5 hr postinfection.

**E3L** expression, however, appears more prolonged, in that it was  
detectable between 3 to 4 hr postinfection while K3L was undetectable after  
3 hr postinfection. Despite having similar expression profiles at early  
times postinfection, a pronounced sensitivity of protein synthesis to IFN  
was observed by 30 min postinfection in VV K3Lsup - virus-infected cells,  
whereas IFN sensitivity was not observed in VV E3Lsup --infected cells  
until 2 hr postinfection. Subsequent analyses of the IFN-induced antiviral  
pathways in VV-infected cells demonstrated that the K3L gene product does  
not contribute to the previously identified specific kinase inhibitory

-more-

?

Display 2/9/3 (Item 1 from file: 71)

DIALOG(R)File 71:ELSEVIER BIOBASE

(c) 2001 Elsevier Science B.V. All rts. reserv.

factor (SKIF) activity but does reduce the level of phosphorylated  
eIF-2alpha in VV-infected cells. Interestingly, the IFN-induced  
2',5'-oligoadenylate synthetase-mediated antiviral pathway was active in VV  
K3Lsup --infected cells and not in wild-type virus-infected cells.  
Collectively these results suggest that the K3Lsup -- and E3Lsup --encoded  
products abrogate the antiviral effect of IFN at distinct levels.

CLASSIFICATION CODE AND DESCRIPTION:

86.7.4.10 - IMMUNOLOGY AND INFECTIOUS DISEASES / IMMUNITY TO INFECTION /  
Medical and Veterinary Virology / Animal **vaccines**

- end of record -

?

Display 2/9/4 (Item 1 from file: 73)  
DIALOG(R)File 73:EMBASE  
(c) 2001 Elsevier Science B.V. All rts. reserv.

11164940 EMBASE No: 2001180941

Regulation of mRNA translation and cellular signaling by hepatitis C  
virus nonstructural protein NS5A

He Y.; Tan S.-L.; Tareen S.U.; Vijaysri S.; Langland J.O.; Jacobs B.L.;  
Katze M.G.

M.G. Katze, Department of Microbiology, Box 358070, University of  
Washington, Seattle, WA 98195 United States

AUTHOR EMAIL: honey@u.washington.edu

Journal of Virology ( J. VIROL. ) (United States) 2001, 75/11  
(5090-5098)

CODEN: JOVIA ISSN: 0022-538X

DOCUMENT TYPE: Journal ; Article

LANGUAGE: ENGLISH SUMMARY LANGUAGE: ENGLISH

NUMBER OF REFERENCES: 59

The NS5A nonstructural protein of hepatitis C virus (HCV) has been shown

-more-

?

Display 2/9/4 (Item 1 from file: 73)  
DIALOG(R)File 73:EMBASE  
(c) 2001 Elsevier Science B.V. All rts. reserv.

to inhibit the cellular interferon (IFN)-induced protein kinase R (PKR).  
PKR mediates the host IFN-induced antiviral response at least in part by  
inhibiting mRNA translation initiation through phosphorylation of the alpha  
subunit of eukaryotic initiation factor 2 (eIF2alpha). We thus examined the  
effect of NS5A inhibition of PKR on mRNA translation within the context of  
virus infection by using a recombinant **vaccinia** virus (VV)-based  
assay. The W **E3L** protein is a potent inhibitor of PKR. Accordingly,  
infection of IFN-pretreated HeLa S3 cells with an **E3L**-deficient W  
(VVAE3L) resulted in increased phosphorylation levels of both PKR and  
eIF2alpha. IFN-pretreated cells infected with VV in which the **E3L**  
locus was replaced with the NS5A gene (VVNS5A) displayed diminished  
phosphorylation of PKR and eIF2alpha in a transient manner. We also  
observed an increase in activation of p38 mitogen-activated protein kinase  
in IFN-pretreated cells infected with VVDELTA**E3L**, consistent with reports  
that p38 lies downstream of the PKR pathway. Furthermore, these cells  
exhibited increased phosphorylation of the capbinding initiation factor 4E  
(eIF4E), which is downstream of the p38 pathway. Importantly, these effects

-more-

?

Display 2/9/4 (Item 1 from file: 73)  
DIALOG(R)File 73:EMBASE  
(c) 2001 Elsevier Science B.V. All rts. reserv.

were reduced in cells infected with VVNS5A. NS5A was also found to inhibit  
activation of the p38-eIF4E pathway in epidermal growth factor-treated

cells stably expressing NS5A. NS5A-induced inhibition of eIF2alpha and eIF4E phosphorylation may exert counteracting effects on mRNA translation. Indeed, IFN-pretreated cells infected with VVNS5A exhibited a partial and transient restoration of cellular and viral mRNA translation compared with IFN-pretreated cells infected with VVDELTA3L. Taken together, these results support the role of NS5A as a PKR inhibitor and suggest a potential mechanism by which HCV might maintain global mRNA translation rate during early virus infection while favoring cap-independent translation of HCV mRNA during late infection.

DRUG DESCRIPTORS:

\*messenger RNA--endogenous compound--ec; \*virus RNA--endogenous compound--ec; \*virus protein--endogenous compound--ec  
protein kinase--endogenous compound--ec; **vaccinia vaccine**;  
interferon; alpha2 interferon--endogenous compound--ec; mitogen activated

-more-

?

Display 2/9/4 (Item 1 from file: 73)

DIALOG(R)File 73:EMBASE

(c) 2001 Elsevier Science B.V. All rts. reserv.

protein kinase--endogenous compound--ec; synaptophysin--endogenous compound--ec; initiation factor 4E--endogenous compound--ec; epidermal growth factor; unclassified drug

MEDICAL DESCRIPTORS:

\*RNA translation; \*Hepatitis C virus

virus infection; HeLa cell; protein phosphorylation; virus gene; signal transduction; cell communication; human; nonhuman; human cell; article; priority journal

DRUG TERMS (UNCONTROLLED): protein kinase r--endogenous compound--ec

CAS REGISTRY NO.: 9026-43-1 (protein kinase); 142243-02-5 (mitogen activated protein kinase); 62229-50-9 (epidermal growth factor)

SECTION HEADINGS:

004 Microbiology: Bacteriology, Mycology, Parasitology and Virology

- end of record -

?

Display 2/9/5 (Item 2 from file: 73)

DIALOG(R)File 73:EMBASE

(c) 2001 Elsevier Science B.V. All rts. reserv.

06215373 EMBASE No: 1995254229

A pilot study demonstrating the feasibility of using intratumoral **vaccinia** injections as a vector for gene transfer

Mastrangelo M.J.; Maguire Jr. H.C.; McCue P.; Lee S.S.; Alexander A.; Nazarian L.N.; Eisenlohr L.C.; Nathan F.; Berd D.; Lattime E.C.

Department of Medicine, Jefferson Medical College, 1015 Walnut Street, Philadelphia, PA 19107 United States

Vaccine Research ( VACCINE RES. ) (United States) 1995, 4/2 (55-69)

CODEN: VAREE ISSN: 1056-7909

DOCUMENT TYPE: Journal; Article

LANGUAGE: ENGLISH SUMMARY LANGUAGE: ENGLISH

It has been hypothesized that the acquisition of tumor-specific immunity can be enhanced by enrichment of the cytokine milieu at the site of immunization. As a prelude to exploring the utility of intratumoral injection of **vaccinia** virus recombinants as in vivo insertion vectors

-more-

?

Display 2/9/5 (Item 2 from file: 73)  
DIALOG(R)File 73:EMBASE  
(c) 2001 Elsevier Science B.V. All rts. reserv.  
for cytokine genes, we first demonstrated that three human melanoma cell lines could be infected in vitro with successful expression of the reporter gene product (influenza nuclear protein). In a subsequent pilot study, five patients with dermal, subcutaneous and/or lymph node metastases from cutaneous melanoma were revaccinated with wild-type **vaccinia** virus and, 4 days later, twice weekly intratumoral injections of the same virus were begun. Escalating doses of up to 10sup 7 pock-forming units (PFU) were safely administered repeatedly with modest local (erythema and induration) and mild systemic (flu-like symptoms) reactions. Four of five patients developed antivaccinia virus antibody titers  $\geq 1/3200$ . With rising antibody titers, local and systemic reactions waned. One patient with a large exophytic lesion experienced dramatic tumor regression with multiple injections of 10sup 7 PFU of virus. Most importantly sequential biopsies of this lesion over a 2-month period demonstrated repeated infection with successful production of viral gene product (**E3L**) despite antiviral antibody titers as high as 1/12,800. These data demonstrate that **vaccinia** virus can be safely administered repeatedly intralesionally

-more-

?

Display 2/9/5 (Item 2 from file: 73)  
DIALOG(R)File 73:EMBASE  
(c) 2001 Elsevier Science B.V. All rts. reserv.  
and that viral gene function can be maintained for a protracted period even in the face of substantial antiviral antibody titers. We hypothesize that a passenger cytokine gene would function similarly and mediate an immunoadjuvant effect.

#### DRUG DESCRIPTORS:

\*tumor **vaccine**--adverse drug reaction--ae; \*tumor **vaccine**--drug therapy--dt; \*tumor **vaccine**--clinical trial--ct  
carmustine--drug therapy--dt; carmustine--drug combination--cb; cisplatin--drug therapy--dt; cisplatin--drug combination--cb; cytokine--endogenous compound--ec; dacarbazine--drug combination--cb; dacarbazine--drug therapy--dt; gene product; immunological adjuvant; tamoxifen--drug combination--cb; tamoxifen--drug therapy--dt; virus antibody--endogenous compound--ec

#### MEDICAL DESCRIPTORS:

\*gene transfer  
adult; aged; antibody titer; article; chill--side effect--si; clinical article; clinical trial; controlled study; erythema--side effect--si;

-more-

?

Display 2/9/5 (Item 2 from file: 73)  
DIALOG(R)File 73:EMBASE  
(c) 2001 Elsevier Science B.V. All rts. reserv.  
female; fever--side effect--si; gene insertion; human; human cell; human tissue; immunization; intratumoral drug administration; lymph node metastasis--drug therapy--dt; lymphadenopathy--side effect--si; male; melanoma cell; myalgia--side effect--si; priority journal; pustule--side

effect--si; reporter gene; skin metastasis--drug therapy--dt; skin necrosis  
--side effect--si; tumor biopsy; tumor immunity; tumor regression;

**vaccinia** virus; virus recombinant

CAS REGISTRY NO.: 154-93-8 (carmustine); 15663-27-1, 26035-31-4, 96081-74-2  
(cisplatin); 4342-03-4 (dacarbazine); 10540-29-1 (tamoxifen)

SECTION HEADINGS:

- 013 Dermatology and Venereology
- 016 Cancer
- 026 Immunology, Serology and Transplantation
- 037 Drug Literature Index
- 038 Adverse Reaction Titles

- end of record -

?

Display 2/9/6 (Item 1 from file: 144)  
DIALOG(R)File 144:Pascal  
(c) 2001 INIST/CNRS. All rts. reserv.

14500075 PASCAL No.: 00-0163154

ETUDE DES PROTEINES DU VIRUS DE LA **VACCINE** QUI SONT SYNTHETISEES  
AVANT LA REPLICATION DE L'ADN VIRAL DANS LES CELLULES INFECTEES ET QUI SONT  
ASSOCIEES AUX VIROSOMES

(Study of early proteins associated with virosomes in **vaccinia**  
virus-infected cells)

MURCIA NICOLAS Adriana; BEAUD Georges, dir  
Universite de Compiègne, Compiègne, Francee

Univ.: Universite de Compiègne. Compiègne. FRA Degree: Th. doct.  
1999-07; 1999 75 p.

Availability: INIST-T 129678; T99COMP1212 0000; RBCCN-601592101;  
T99COMP1212 0000

No. of Refs.: 83 ref.

Document Type: T (Thesis) ; M (Monographic)

Country of Publication: France

Language: French Summary Language: French; English

-more-

?

Display 2/9/6 (Item 1 from file: 144)  
DIALOG(R)File 144:Pascal  
(c) 2001 INIST/CNRS. All rts. reserv.

Le virus de la **vaccine** (Poxviridac) se replique dans les cellules  
de la plupart de mammiferes et presente la particularite (avec tous les  
poxvirus) de transcrire ses genes, de repliquer son ADN (193 kb) et de  
s'assembler dans le cytoplasme des cellules infectees. L'ADN viral  
neosynthetise est associe a des sites granulaires, denses appelees  
virosomes. Pendant les premieres etapes du cycle viral, pratiquement tout  
l'ADN est associe a ces complexes et il en est ensuite libere au cours de  
l'assemblage du virus de la **vaccine**. Dans la premiere partie de ce  
travail nous avons identifie par spectrometrie de masses trois proteines  
virales codees par les genes H5R, **E3L** et E5L synthetisees avant la  
replication de l'ADN viral et qui sont majoritairement associees aux  
virosomes. Ce travail caracterise la phosphoproteine H5R comme le composant  
majeur des virosomes. La proteine **E3L** est une proteine inhibitrice de  
la proteine kinase PKR induite par l'interferon. Le gene E5L est  
relativement bien conserve entre les differents poxvirus mais il n'est pas  
essentiel pour le developpement viral sur trois lignees cellulaires. Dans  
la deuxieme partie, nous avons montre que ces trois proteines virales

-more-

?

Display 2/9/6 (Item 1 from file: 144)  
DIALOG(R)File 144:Pascal  
(c) 2001 INIST/CNRS. All rts. reserv.  
precoces s'associent, dans les cellules infectees en presence d'un inhibiteur de la replication de l'ADN, a des particules sedimentant moins vite que les virions infectieux. La troisieme partie porte sur la proteine kinase BIR qui est synthetisee a l'etape precoce et qui se localise dans les virosomes essentielle pour la replication de l'ADN viral. La proteine kinase BIR phosphoryle les proteines ribosomiques S2 et S4 des cellules infectees. Nous avons exprime de facon transitoire la proteine BIR dans des cellules HeLa et observe les effets de l'expression de cette proteine sur l'expression d'un gene rapporteur.

English Descriptors: **Vaccinia** virus; Protein; Early; Characterization  
; Molecular weight determination; Infected cell; Molecular association  
Broad Descriptors: Orthopoxvirus; Chordopoxvirinae; Poxviridae; Virus;  
Orthopoxvirus; Chordopoxvirinae; Poxviridae; Virus; Orthopoxvirus;  
Chordopoxvirinae; Poxviridae; Virus

French Descriptors: Virus **vaccine**; Proteine; Precoce; Caracterisation

-more-

?

Display 2/9/6 (Item 1 from file: 144)  
DIALOG(R)File 144:Pascal  
(c) 2001 INIST/CNRS. All rts. reserv.  
; Determination masse moleculaire; Cellule infectee; Association  
moleculaire; Virosome

Classification Codes: 002A05C03

Copyright (c) 2000 INIST-CNRS. All rights reserved.

- end of record -

?

Display 2/9/7 (Item 2 from file: 144)  
DIALOG(R)File 144:Pascal  
(c) 2001 INIST/CNRS. All rts. reserv.  
  
11165620 PASCAL No.: 93-0674875  
Nuclear localization of a double-stranded RNA-binding protein encoded by the **vaccinia** virus **E3L** gene  
HAO YUWEN; COX J H; YEWDELL J W; BENNINK J R; MOSS B  
NIH, national inst. allergy infectious diseases, lab. viral diseases,  
Bethesda MD 20892, USA  
Journal: Virology : (New York, NY), 1993, 195 (2) 732-744  
ISSN: 0042-6822 CODEN: VIRLAX Availability: INIST-7801;  
354000035101210440  
No. of Refs.: 1 p.  
Document Type: P (Serial) ; A (Analytic)  
Country of Publication: USA  
Language: English

We produced a B cell hybridoma (TW2.3) from **vaccinia** virus-infected mice that secreted a monoclonal antibody (MAB) reactive with a 25-kDA early viral protein that was localized by laser scanning confocal microscopy to

-more-

?

Display 2/9/7 (Item 2 from file: 144)  
DIALOG(R) File 144:Pascal  
(c) 2001 INIST/CNRS. All rts. reserv.  
the nucleus and cytoplasmic viral factory regions of infected cells. By cell-free translation of mRNA selected by hybridization to a complete library of **vaccinia** virus DNA fragments, the immunoreactive polypeptide was mapped to open reading frame **E3L**. The RNA start site of an early promoter was located 26 nucleotides upstream of the first methionine codon of **E3L**. Evidence was obtained that translation initiation occurs in vivo and in vitro at both the first and second methionine codons to produce major and minor polypeptides of 25 and 19 kDa, respectively

English Descriptors: **Vaccinia** virus; Double stranded RNA; Nuclear protein; Localization; Cell nucleus; Infected cell; Cell line; Host virus relation; RNA binding protein

Broad Descriptors: Orthopoxvirus; Chordopoxvirinae; Poxviridae; Virus; Orthopoxvirus; Chordopoxvirinae; Poxviridae; Virus; Orthopoxvirus; Chordopoxvirinae; Poxviridae; Virus

-more-

?

Display 2/9/7 (Item 2 from file: 144)  
DIALOG(R) File 144:Pascal  
(c) 2001 INIST/CNRS. All rts. reserv.  
French Descriptors: Virus **vaccine**; RNA bicatenaire; Proteine nucleaire; Localisation; Noyau cellulaire; Cellule infectee; Lignee cellulaire; Relation hote virus; Gene **E3L**; Proteine liaison RNA

Classification Codes: 002A05C04

- end of record -

?

Display 2/9/8 (Item 3 from file: 144)  
DIALOG(R) File 144:Pascal  
(c) 2001 INIST/CNRS. All rts. reserv.  
11069107 PASCAL No.: 93-0576117  
Identification of a conserved motif that is necessary for binding of the **vaccinia** virus **E3L** gene products to double-stranded RNA  
HWAI-WEN CHANG; JACOBS B L  
Arizona State univ., dep. microbiology, molecular cellular biology  
graduate degree program, Tempe AZ 85287-2701, USA  
Journal: Virology : (New York, NY), 1993, 194 (2) 537-547  
ISSN: 0042-6822 CODEN: VIRLAX Availability: INIST-7801;  
354000033910680110  
No. of Refs.: 1 p.  
Document Type: P (Serial) ; A (Analytic)  
Country of Publication: USA

Language: English

The **E3L** gene of **vaccinia** virus encodes the double-stranded (ds) RNA binding proteins p20 and p25 that exhibit inhibitory activity for the IFN-induced, P SUB 1 /eIF-2 alpha protein kinase. A region in the

-more-

?

Display 2/9/8 (Item 3 from file: 144)

DIALOG(R)File 144:Pascal

(c) 2001 INIST/CNRS. All rts. reserv.

**E3L** encoded proteins (residues 156-180) shares a high degree of similarity with several proteins that bind double-helical RNA including the P SUB 1 /eIF-2 alpha kinase, bacterial and yeast RNase III, and a human transactivator response element/Rev response element binding protein. In this study, mutants of **E3L** proteins were constructed in order to determine the region of the proteins required for dsRNA binding and kinase inhibitory activity. Our data indicate that both the region necessary for dsRNA binding and for kinase inhibitory activity are located at the carboxyl terminus of the protein

English Descriptors: **Vaccinia** virus; Proteins; Property structure relationship; C terminal-Sequence; Molecular interaction; Double stranded RNA; Inhibition; Protein kinase

Broad Descriptors: Orthopoxvirus; Chordopoxvirinae; Poxviridae; Virus; Enzyme; Orthopoxvirus; Chordopoxvirinae; Poxviridae; Virus; Enzyme; Orthopoxvirus; Chordopoxvirinae; Poxviridae; Virus; Enzima

-more-

?

Display 2/9/8 (Item 3 from file: 144)

DIALOG(R)File 144:Pascal

(c) 2001 INIST/CNRS. All rts. reserv.

French Descriptors: Virus **vaccine**; Proteine; Relation structure propriete; Sequence C terminale; Interaction moleculaire; RNA bicatenaire ; Inhibition; Protein kinase; Proteine EL3

Classification Codes: 002A05C05

- end of record -

?

Display 2/9/9 (Item 4 from file: 144)

DIALOG(R)File 144:Pascal

(c) 2001 INIST/CNRS. All rts. reserv.

10932446 PASCAL No.: 93-0441809

The **E3L** and **K3L** **vaccinia** virus gene products stimulate translation through inhibition of the double-stranded RNA-dependent protein kinase by different mechanisms

DAVIES M V; HWAI-WEN CHANG; JACOBS B L; KAUFMAN R J  
Genetics inst., Cambridge MA 02140, USA

Journal: Journal of virology, 1993, 67 (3) 1688-1692

ISSN: 0022-538X Availability: INIST-13592; 354000039238860670

No. of Refs.: 17 ref.

Document Type: P (Serial) ; A (Analytic)

Country of Publication: USA

Language: English

**Vaccinia** virus has evolved multiple mechanisms to counteract the interferon-induced antiviral host cell response. Recently, two **vaccinia** virus gene products were shown to interfere with the activity of the double-stranded RNA-dependent protein kinase (PKR): the K3L

-more-

?

Display 2/9/9 (Item 4 from file: 144)  
DIALOG(R)File 144:Pascal  
(c) 2001 INIST/CNRS. All rts. reserv.  
gene product and the **E3L** gene product. We have evaluated the efficiency by which these gene products inhibit PKR and whether they act in a synergistic manner. The effects of the two **vaccinia** virus gene products were compared in an in vivo system in which translation of a reporter gene (dihydrofolate reductase or eukaryotic translation initiation factor 2 alpha (eIF-2 alpha )) was inhibited because of the localized activation of PKR

English Descriptors: **Vaccinia** virus; Genetical translation; Activation; Mechanism of action; Initiation factor eIF2; Alpha-Peptide chain; Phosphorylation; Synergism; Biological activity  
Broad Descriptors: Orthopoxvirus; Chordopoxvirinae; Poxviridae; Virus; Enzyme; Orthopoxvirus; Chordopoxvirinae; Poxviridae; Virus; Enzyme; Orthopoxvirus; Chordopoxvirinae; Poxviridae; Virus; Enzima

French Descriptors: Virus **vaccine**; Traduction genetique; Activation; Mecanisme action; Facteur initiation eIF2; Chaîne peptidique alpha ;

-more-

?

Display 2/9/9 (Item 4 from file: 144)  
DIALOG(R)File 144:Pascal  
(c) 2001 INIST/CNRS. All rts. reserv.  
Phosphorylation; Synergie; Activite biologique; Proteine **E3L**;  
Proteine K3L; Double stranded RNA-dependent protein kinase

Classification Codes: 002A05C05

- end of record -

?

Display 2/9/10 (Item 5 from file: 144)  
DIALOG(R)File 144:Pascal  
(c) 2001 INIST/CNRS. All rts. reserv.  
  
10222301 PASCAL No.: 92-0428204  
The **E3L** gene of **vaccinia** virus encodes an inhibitor of the interferon-induced, double-stranded RNA-dependent protein kinase  
HWAI-WEN CHANG; WATSON J C; JACOBS B L  
Arizona state univ., dep. microbiology, Tempe AZ 48287-2701, USA  
Journal: Proceedings of the National Academy of Sciences of the United States of America, 1992, 89 (11) 4825-4829  
ISSN: 0027-8424 CODEN: PNASA6 Availability: INIST-574;  
354000028272290100  
No. of Refs.: 32 ref.

Document Type: P (Serial) ; A (Analytic)

Country of Publication: USA

Language: English

A **vaccinia** virus-encoded double-stranded RNA-binding protein, p25, has been previously implicated in inhibition of the interferon-induced, double-stranded RNA-activated protein kinase. In this study, we have

-more-

?

Display 2/9/10 (Item 5 from file: 144)

DIALOG(R)File 144:Pascal

(c) 2001 INIST/CNRS. All rts. reserv.

identified the **vaccinia** viral gene (WR strain) that encodes p25. Amino acid sequence analysis of a chymotryptic fragment of p25 revealed a close match to the **vaccinia** virus (Copenhagen strain) **E3L** gene. The WR strain **E3L** gene was cloned and expressed either in COS-1 cells or in rabbit reticulocyte lysates in vitro

English Descriptors: Enzyme inhibitor; Gene product; Molecular cloning; Primary structure; **Vaccinia** virus; RNA binding protein

Broad Descriptors: Orthopoxvirus; Chordopoxvirinae; Poxviridae; Virus; Enzyme; Orthopoxvirus; Chordopoxvirinae; Poxviridae; Virus; Enzyme; Orthopoxvirus; Chordopoxvirinae; Poxviridae; Virus; Enzima

French Descriptors: Inhibiteur enzyme; Produit gene; Clonage moleculaire; Structure primaire; Virus **vaccine**; Gene **E3L**; Double-stranded RNA-dependent protein kinase; Proteine liaison RNA

-more-

?

Display 2/9/10 (Item 5 from file: 144)

DIALOG(R)File 144:Pascal

(c) 2001 INIST/CNRS. All rts. reserv.

Classification Codes: 002A05C05

- end of record -

?

Display 2/9/11 (Item 1 from file: 357)

DIALOG(R)File 357:Derwent Biotechnology Abs

(c) 2001 Derwent Publ Ltd. All rts. reserv.

0264191 DBA Accession No.: 2001-03945 PATENT

**Vaccinia** virus with amino acids deleted from the **E3L** gene product, which reduces virulence and improves efficacy, useful as a **vaccine** - recombinant **vaccinia** virus and immunization in mouse for **vaccine** and **vaccinia** virus infection therapy

AUTHOR: Jacobs B; Brandt T

CORPORATE SOURCE: Tempe, AZ, USA.

PATENT ASSIGNEE: Univ.Arizona-State 2000

PATENT NUMBER: WO 200073487 PATENT DATE: 20001207 WPI ACCESSION NO.: 2001-041152 (2005)

PRIORITY APPLIC. NO.: US 136277 APPLIC. DATE: 19990527

NATIONAL APPLIC. NO.: WO 2000US10948 APPLIC. DATE: 20000420

LANGUAGE: English

ABSTRACT: **Vaccinia** viruses from which the region encoding at least

amino acids 1-37 of the **E3L** gene product has been deleted, are claimed. Also claimed are: a recombinant **vaccinia** virus

-more-

?

Display 2/9/11 (Item 1 from file: 357)  
DIALOG(R)File 357:Derwent Biotechnology Abs  
(c) 2001 Derwent Publ Ltd. All rts. reserv.  
WR-delta-83N; a composition containing the **vaccinia** virus and a carrier; and a composition containing a recombinant **vaccinia** virus WR-delta-83N and a carrier. A virus (WR, WR-delta-**E3L** or WR-delta-83N) was amplified by infection of RK13 cells until 100% cytopathic effect was observed. Cells were scraped and resuspended in 1 mM Tris, pH 8.8. Amplified viruses were lysed and debris was removed by centrifugation. Supernatant was used for mouse infections. Three to 4 wk old c57b16 mice were anesthetized and mice were subsequently infected with 10 ul of virus or a dilution of virus intranasally in their cages and observed for pathogenesis and death. Intranasal inoculation with WR resulted in death at 10(4) pfu, whereas no pathogenesis could be detected with WR-delta-**E3L** at the highest dose. With WR-delta-83N, 10(7) pfu was required for death, indicating that the N-terminus of **E3L** is an important determinant for virus virulence. The recombinant virus is useful as a **vaccine**. (12pp)  
DESCRIPTORS: recombinant **vaccinia** virus, immunization in mouse, appl. recombinant **vaccine**, **vaccinia** virus infection therapy pox

-more-

?

Display 2/9/11 (Item 1 from file: 357)  
DIALOG(R)File 357:Derwent Biotechnology Abs  
(c) 2001 Derwent Publ Ltd. All rts. reserv.  
virus mammal animal (Vol.20, No.8)  
SECTION: PHARMACEUTICALS-**Vaccines**; GENETIC ENGINEERING AND  
FERMENTATION-Nucleic Acid Technology (D4,A1)

- end of display -

?

>>>Page beyond end of display invalid

?

PLEASE ENTER A COMMAND OR BE LOGGED OFF IN 5 MINUTES

?